araag2/HINT huggingface dataset:
Clinical trial NCT00716547 (phase 3, status: completed)
Conditions: osteoarthritis of the knee
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: ketoprofen in diractin®, ketoprofen in diractin®, placebo, celecoxib
SMILES: CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1, CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Informed consent signed and dated

          -  Age > 45 years

          -  Class I-III OA of the knee and subject meets American College of Rheumatology (ACR)
             clinical classification criteria for osteoarthritis of the knee

        Exclusion Criteria:

          -  Skin lesions or dermatological diseases in the treatment area

          -  Directly or indirectly involved in the conduct and administration of this study

          -  Received any investigational medicinal product within 30 days prior to Screening Visit
             or participation in any previous clinical study with Diractin®

          -  Pregnancy or lactation

          -  Residents of psychiatric wards, prisons or other state institutions

          -  Malignancy within the past 2 years

          -  Depressive disorders requiring treatment with tricyclics, treatment with other
             antidepressants must be stable for 3 months prior to screening and throughout the
             study

          -  Epilepsy

          -  Schizophrenia

          -  Neuropathic pain and any other pain condition requiring chronic use of pain medication

          -  Known hypersensitivity or allergy (including photoallergy) to NSAID´s including
             ketoprofen, celecoxib, sulfonamides and ingredients used in pharmaceutical products
             including galactose

          -  Peripheral arterial disease and/or cerebrovascular disease

          -  History of stroke or myocardial infarction

          -  Congestive Heart failure NYHA Class II-IV

          -  History of pancreatitis or peptic ulcers;

          -  Inflammatory GI disease (e.g. M. Crohn, colitis ulcerosa)

          -  Serum creatinine levels > 2.5 milligrams/deciliter (mg/dL)

          -  ALT or AST levels ≥ 5 times the ULN

          -  Unable to discontinue analgesic therapy including opioids, NSAID´s, tramadol, muscle
             relaxants, gabapentin, pregabalin, duloxetine, venlafaxine, capsaicine or other drugs
             approved or used for the treatment of pain for the duration of the study
Clinical trial NCT00006708 (phase 3, status: terminated)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: carboplatin, etoposide, ifosfamide
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, N[C@@H](CCCNC(N)=N)C(O)=O
Reason stopped: 
    lack of accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically proven aggressive B-cell non-Hodgkin's lymphoma
        that has failed prior combination chemotherapy with an anthracycline-containing regimen
        Eligible histologies: Diffuse large cell Small non-cleaved cell/Burkitt's lymphoma No
        lymphoblastic or mantle cell lymphoma First relapse or primary refractory disease
        Ineligible for or refused treatment with salvage chemotherapy followed by high-dose therapy
        and autologous stem cell rescue Documented CD20 antigen expression Measurable disease No
        clinical evidence of CNS involvement by lymphoma

        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: Zubrod 0-2 Life expectancy: Not
        specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 2 times upper
        limit of normal Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance greater
        than 60 mL/min Other: HIV negative Not pregnant or nursing Fertile patients must use
        effective contraception No other malignancy within the past 5 years except adequately
        treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix

        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics No prior rituximab
        Chemotherapy: See Disease Characteristics Endocrine therapy: Not specified Radiotherapy:
        Not specified Surgery: Not specified Other: Recovered from toxic effects of all prior
        therapy No other concurrent therapy unless disease progression occurs
Clinical trial NCT00358215 (phase 3, status: completed)
Conditions: heart failure, anemia, cardiovascular disease, ventricular dysfunction, congestive heart failure
ICD codes: I50.814, I09.81, I50.82, I50.89, I50.9, T86.22, I11.0, D53.2, D64.9, D46.4, D53.0, D53.9, D61.3, D61.9, A52.00, A52.09, A50.54, Z01.810, Q87.418, Z13.6, R94.30, I47.2, I49.01, I49.02, I49.3, Q21.0, I47.0, I50.1, I50.20, I50.21, I50.22, I50.30, I50.31, I50.32, I50.40
Drugs: darbepoetin alfa, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Heart failure of at least 3 months duration and of New York Heart Association (NYHA)
             class II, III, or IV

          -  hemoglobin between 9.0 g/dL and 12.0 g/dL

          -  left ventricular ejection fraction equal to or less than 40%

        Exclusion Criteria:

          -  Transferrin saturation (Tsat) < 15%

          -  Blood pressure > 160/100 mm Hg

          -  Heart failure primarily due to valvular heart disease or clinically significant
             valvular heart disease that might lead to surgical correction within 12 months of
             randomization

          -  Recipient of a major organ transplant or receiving renal replacement therapy

          -  Serum creatinine > 3.0 mg/dL (> 265 µmol/L)
Clinical trial NCT01239030 (phase 3, status: completed)
Conditions: attention deficit hyperactivity disorder, adhd
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: methylphenidate hydrochloride extended release capsules
SMILES: COC(=O)C(C1CCCCN1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females ages 6 up to 18

          -  ADHD diagnosis with ADHD-RS-IV scores ≥ 90th percentile

          -  In need of treatment for ADHD and able to have 2-day washout from previous medication

          -  Females of child-bearing potential not pregnant and practice birth control

          -  Subject and parent/guardian willing to comply with protocol

          -  Signed consent and assent

        Exclusion Criteria:

          -  IQ less than 80 Wechsler Abbreviated Scale of Intelligence (WASI)

          -  Current primary psychiatric diagnosis of other listed disorders

          -  Chronic medical illnesses: seizure, hypertension, thyroid disease, cardiac, family
             history of sudden death, glaucoma

          -  Use of psychotropic central nervous system (CNS) meds having effect exceeding 14 days
             from screening

          -  Planned use of prohibited drugs

          -  Is pregnant or breast-feeding

          -  Significant ECG or laboratory abnormalities

          -  Experimental drug or medical device within 30 days prior to screening

          -  Hypersensitivity to methylphenidate

          -  Inability or unwillingness to comply with protocol

          -  Well controlled on current ADHD treatment

          -  Inability to take oral capsules
Clinical trial NCT01787188 (phase 3, status: completed)
Conditions: osteoarthritis
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: meloxicam test capsules, meloxicam test capsules, placebo capsules
SMILES: CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=C(C=CC=C2)S1(=O)=O, CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=C(C=CC=C2)S1(=O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Primary diagnosis of Functional Class I-III OA of the hip or knee

          -  Chronic user of nonsteroidal anti-inflammatory drugs (NDAIDs) and/or acetaminophen for
             OA pain

          -  Discontinued all analgesic therapy at Screening

          -  For women of child-bearing potential: a woman who is not pregnant and not nursing, and
             who is practicing an acceptable method of birth control

        Exclusion Criteria:

          -  History of allergic reaction or clinically significant intolerance to acetaminophen,
             aspirin, or any NSAIDs, including meloxicam

          -  Requires continuous use of opioid or opioid combination products to control OA pain of
             the knee or hip

          -  Clinically significant unstable cardiac, respiratory, neurological, immunological,
             hematological, or renal disease

          -  Significant difficulties swallowing capsules or unable to tolerate oral medication

          -  Previous participation in another clinical study of Meloxicam Capsules or received any
             investigational drug or device or investigational therapy within 30 days before
             Screening
Clinical trial NCT00257166 (phase 3, status: completed)
Conditions: bipolar disorder
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32
Drugs: ziprasidone oral capsules, placebo oral capsules
SMILES: ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  DSM-IV criteria for Bipolar I disorder (manic or mixed); age 10 - 17 years

        Exclusion Criteria:

          -  Imminent risk of suicide or homicide, as judged by the site investigator; any history
             of serious or unstable medical illness, including risk for QT prolongation
Clinical trial NCT00210860 (phase 3, status: completed)
Conditions: migraine
ICD codes: G43.B1, G43.D1, G43.B0, G43.D0, G43.A1, G43.411, G43.419
Drugs: topiramate
SMILES: [H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of migraine with or without aura

          -  Successfully finished CAPSS-277 study

          -  In generally good health

          -  Able to take medicine orally

          -  If female, using birth control

        Exclusion Criteria:

          -  Not having a more painful condition than the headache pain

          -  Cannot be taking any other medications not allowed by the study

          -  Abnormal liver tests

          -  Not compliant with study medication during the CAPSS-277 study

          -  Pregnant or breast-feeding
Clinical trial NCT00087802 (phase 3, status: completed)
Conditions: carcinoma, non-small-cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: gemcitabine/eloxatin (gemox), carboplatin/paclitaxel (cp)
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Newly diagnosed, Stage IIIb or IV NSCLC, chemo or other systemic therapy naive

          -  One (1) unidimensionally measurable lesion

          -  ECOG Performance Status of 0 or 1, no peripheral neuropathy >Grade 1

          -  Patients with clinically stable brain metastases on a stable dose of (or no longer
             requiring) dexamethasone at registration will be eligible. Patients who have received
             cranial radiation for brain metastases must be at least 4 weeks from last radiation
             treatment.

          -  Recovery in full from any previous surgical procedure

          -  No history of an acute cardiac or CNS event within 6 months of entry or current
             clinical evidence of congestive heart failure or non-stable coronary artery disease

        Exclusion Criteria:

          -  Hypersensitivity to any of the 4 study drugs

          -  Concurrent immunotherapy or participation in any investigational drug study within 4
             weeks

          -  Serious uncontrolled intercurrent medical or psychiatric illness and organ allograft

          -  History of other malignancy within the last 5 years (except for squamous or basal cell
             carcinoma of the skin, carcinoma in situ of the cervix, or superficial transitional
             cell carcinoma of the bladder)

          -  Patient is a pregnant or lactating female
Clinical trial NCT01323192 (phase 3, status: completed)
Conditions: attention-deficit hyperactivity disorder
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: jns001, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who meet the criteria of ADHD (predominantly inattentive type [314.00],
             predominantly hyperactive-impulsive type [314.01], and combined type [314.01]) of
             DSM-IV-TR both at present and in childhood, based on Conners' Adult ADHD Diagnostic
             Interview for DSM-IV (CAADID) at screening

          -  DSM-IV Total ADHD Symptoms scores (18 items) of CAARS-O: SV score of = 24 as
             determined by investigator or co-investigator at baseline

          -  Healthy on the basis of physical examination, medical history, vital signs, 12-lead
             ECG and clinical laboratory tests performed at screening

          -  Women of childbearing potential must have a negative urine pregnancy test at screening

          -  Patients (and their legally-acceptable representative if patients are 18 or 19 years
             of age) must have signed an informed consent form (ICF), indicating that they
             understand the purpose of and procedures required for the study and are willing to
             participate in the study.

        Exclusion Criteria:

          -  Presence or history of co-morbid psychiatric diagnosis per DSM-IV-TR criteria of
             bipolar I disorder, schizophrenia, schizoaffective disorder, or severe obsessive
             compulsive disorders

          -  Presence of co-morbid psychiatric diagnosis per DSM-IV-TR criteria of pervasive
             developmental disorder (including autistic disorder or Asperger's disorder),
             suicidality, or any other diagnosis that in the judgment the investigator or
             co-investigator would exclude the patient from the study

          -  Presence of motor tics, history of Tourette's disorder, or family history of
             Tourette's disorder

          -  Known or suspected mental retardation
Clinical trial NCT00005113 (phase 3, status: terminated)
Conditions: end-stage renal disease, kidney transplantation
ICD codes: N18.6, I12.0, I13.11, I13.2, N26.2, Q63.0, Q63.2, Z52.4, I75.81, N19, N20.0
Drugs: cyclosporine, sirolimus, tacrolimus
SMILES: CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O
Reason stopped: 
    inability to meet the accrual target of 213.
  
Eligibility criteria:

        Inclusion Criteria

        Your child may be eligible for this study if he/she:

          -  Has received a kidney transplant.

          -  Has experienced 1 or more episodes of acute rejection or chronic rejection; a
             rejection episode must have responded to treatment and have occurred at least 30 days
             before study enrollment.

          -  Has stable kidney function at the time of study enrollment.

          -  Is 20 years of age or younger.

          -  Has written informed consent of parent or guardian if under the age of 18.

          -  Agrees to use birth control during the study and for 3 months following treatment.

        Exclusion Criteria

        Your child will not be eligible for this study if he/she:

          -  Has a history of cancer.

          -  Has received a multi-organ transplant (more than a kidney).

          -  Has an active infection.

          -  Has an abnormal chest X-ray.

          -  Cannot provide a kidney biopsy at time of study entry.

          -  Is allergic to sirolimus.

          -  Has received experimental drugs within 4 weeks of study entry.

          -  Is pregnant.
Clinical trial NCT00639366 (phase 3, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: chemotherapy
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically proven breast carcinoma

               -  Metastatic or locally advanced disease

          -  Must demonstrate HER2 3+ positivity on IHC or 2+ over-expression and FISH test
             demonstrating C-erB2 gene amplification

          -  No known or suspected brain metastases or CNS disease, as defined by the presence of
             any of the following key symptoms:

               -  Headache

               -  Nausea and/or vomiting

               -  Clinical signs of raised intracranial pressure

               -  Seizures

               -  Focal symptoms

               -  Cognitive dysfunction

               -  Affective disorder

          -  Hormone receptor status not specified

        PATIENT CHARACTERISTICS:

          -  Female

          -  Postmenopausal status not specified

          -  ECOG performance status 0 or 1

          -  Patients must a-priori be suitable for trastuzumab (Herceptin®) +/- chemotherapy in
             terms of bone marrow, hepatic, and renal function

          -  No prior history of cerebrovascular disease or neurological disorder including
             seizures

        PRIOR CONCURRENT THERAPY:

          -  No prior cranial radiotherapy

          -  No prior neurosurgery
Clinical trial NCT01007435 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: tocilizumab, placebo to tocilizumab, methotrexate, placebo to methotrexate
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients ≥ 18 years of age.

          -  Rheumatoid arthritis of ≤ 2 years duration.

          -  Disease Activity Score 28 (DAS28) > 3.2.

          -  Swollen joint count (SJC) ≥ 4 of 66 joints, tender joint count (TJC) ≥ 6 of 68 joints.

          -  Rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide (anti-CCP) positive
             (if RF and anti-CCP negative > 1 erosion required at screening).

          -  Erythrocyte sedimentation rate (ESR) ≥ 28 mm/h or C-reactive protein (CRP) ≥ 10 mg/L
             at screening.

        Exclusion Criteria:

          -  Previous treatment with tocilizumab.

          -  Previous treatment with methotrexate or biologic agent.

          -  Rheumatic autoimmune disease other than rheumatoid arthritis (RA).

          -  History of or current inflammatory joint disease other than RA.

          -  Functional class IV as defined by the American College of Rheumatology (ACR)
             Classification of Functional Status in RA.
Clinical trial NCT01421147 (phase 3, status: completed)
Conditions: diabetes mellitus, type 1
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: ly2963016, lantus, insulin lispro
SMILES: CN(C)C(=N)NC(N)=N, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have type 1 diabetes mellitus based on the disease diagnostic criteria [World Health
             Organization (WHO) Classification]

          -  Have duration of diabetes greater than or equal to one year

          -  Have Hemoglobin A1c (HbA1c) less than or equal to 11.0%

          -  On basal-bolus insulin therapy for at least 1 year [basal insulin must be once daily
             (QD) injection of human insulin isophane suspension (NPH), Lantus, or detemir and
             combined with mealtime injections of human regular insulin, or insulin analog lispro,
             aspart or glulisine]

          -  Have a body mass index (BMI) of less than or equal to 35 kilograms/square meter
             (kg/m²)

        Exclusion Criteria:

          -  Have had more than one episode of severe low blood sugar (defined as needing someone
             else to help because you had very low blood sugar) within the 6 months before entering
             the study

          -  Have had more than one episode of diabetic ketoacidosis or emergency room visits for
             uncontrolled diabetes leading to hospitalization within the 6 months before entering
             the study

          -  Have known hypersensitivity or allergy to any of the study insulins (insulin glargine
             or insulin lispro) or to excipients of the study insulins

          -  Have significant renal, cardiac, gastrointestinal or liver disease

          -  Have active cancer or cancer within the past 5 years
Clinical trial NCT00390689 (phase 3, status: completed)
Conditions: idiopathic restless legs syndrome
ICD codes: E20.0, I95.0, L50.1, D61.3, G24.2, G24.4, G60.3
Drugs: pramipexole 0.125 mg tablet, pramipexole 0.5 mg tablet
SMILES: CCCN[C@H]1CCC2=C(C1)SC(N)=N2, CCCN[C@H]1CCC2=C(C1)SC(N)=N2
Eligibility criteria:

        Inclusion Criteria:

          1. Male or female patients between 20 and 80 years

          2. Patients with a diagnosis of restless legs syndrome (RLS) according to the following
             diagnosis criteria of National institute of health (NIH)/International restless legs
             syndrome study group (IRLSSG):

               1. An urge to move the legs, usually accompanied or caused by uncomfortable and
                  unpleasant sensations in the legs.

               2. The urge to move or unpleasant sensations begin or worsen during periods of rest
                  or inactivity such as lying or sitting.

               3. The urge to move or unpleasant sensations are partially or totally relieved by
                  movement, such as walking or stretching, at least as long as the activity
                  continues.

               4. The urge to move or unpleasant sensations are worse in the evening or night than
                  during the day or only occur in the evening or night.

          3. Patients with a total score larger than 15 on the IRLS at Visit 2

        Exclusion Criteria:

          1. Premenopausal women who meet any of the following 1) to 3) 1) Patients who are
             pregnant or possibly pregnant 2) Patients who are lactating 3) Patients who wish to
             become pregnant during the study period

          2. Patients who cannot take adequate contraceptive measures

          3. Patients with a history of akathisia induced by neuroleptics

          4. Patients with diabetes mellitus requiring insulin therapy

          5. Patients who are judged to have microcytic anaemia by the investigator or
             sub-investigator

          6. Patients with a history or signs of peripheral neuropathy, myelopathy, multiple
             sclerosis, Parkinson's disease or other neurological diseases that may result in the
             occurrence of secondary RLS in the physical function tests or neurological tests

          7. Patients with other sleep disorders such as abnormal behaviour during Rapid eye
             movement (REM) sleep, narcolepsy and sleep apnoea syndrome (patients with an
             apnoea-hypopnoea index (AHI) exceeding 15 determined by polysomnography at the
             relevant trial site or those with loud snoring at least 5 nights/week and an
             experience of respiratory arrest during sleep or excessive daytime sleepiness)